← Back to Clinical Trials
Recruiting NCT06108336

NCT06108336 Cerebellar Involvement in Cognitive Sequencing

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06108336
Status Recruiting
Phase
Sponsor Johns Hopkins University
Condition Effects of Cerebellar Stimulation on Brain Activation
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2024-03-01
Primary Completion 2026-07-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 50 Years
Study Type INTERVENTIONAL
Interventions
TMS during sequence-demanding taskNo TMS during sequence-demanding taskTMS during non-sequence-demanding task

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2024-03-01 with a primary completion date of 2026-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Although there is increasing recognition that the cerebellum is involved in cognition as well as motor function, the manner in which the cerebellum contributes to cognition is uncertain. One theory that might account for both motor and cognitive contributions of the cerebellum is that the cerebellum is involved in sequencing of relevant events or stimuli. Previous experiments have suggested that disruption of the cerebellum impairs the prediction of the next event in a sequence. The present experiment will examine the impact of cerebellar stimulation on brain activation during the performance of both sequence-demanding and non-sequence-demanding tasks.

Eligibility Criteria

Inclusion Criteria: * 1\) Age 18-50; * 2\) educational attainment of at least 8 years; * 3\) capable of giving informed consent; * 4\) fluent speaker of English by self-report; * 5\) right handed. Exclusion Criteria: * 1\) illicit drug use within 30 days of MRI scanning; * 2\) neurological or systemic disorder which can cause dementia or cognitive dysfunction; * 3\) history of an Axis I psychiatric disorder including substance use disorder; * 4\) history of definite stroke; * 5\) focal lesion on MRI exam; * 6\) uncorrected visual deficits by self-report * 7\) contraindications for MRI scanning * 8\) use of anxiolytic, antidepressant, neuroleptic, or sedative medication * 9\) Additional exclusion criteria recommended by Wassermann for TMS neuromodulation, including: History of seizure or a family history of epilepsy, heart disease, intracardiac lines, increased intracranial pressure, history of head trauma, and history of respiratory disease

Contact & Investigator

Central Contact

John E Desmond, Ph.D.

✉ jdesmon2@jhmi.edu

📞 410-502-3583

Principal Investigator

John E Desmond, Ph.D.

PRINCIPAL INVESTIGATOR

Johns Hopkins University

Frequently Asked Questions

Who can join the NCT06108336 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Effects of Cerebellar Stimulation on Brain Activation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06108336 currently recruiting?

Yes, NCT06108336 is actively recruiting participants. Contact the research team at jdesmon2@jhmi.edu for enrollment information.

Where is the NCT06108336 trial being conducted?

This trial is being conducted at Baltimore, United States.

Who is sponsoring the NCT06108336 clinical trial?

NCT06108336 is sponsored by Johns Hopkins University. The principal investigator is John E Desmond, Ph.D. at Johns Hopkins University. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology